Insider Selling: Quantum-Si (NASDAQ:QSI) Insider Sells $14,506.56 in Stock

Quantum-Si Incorporated (NASDAQ:QSI) insider John Vieceli sold 15,111 shares of Quantum-Si stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $0.96, for a total value of $14,506.56. Following the transaction, the insider owned 1,155,546 shares in the company, valued at approximately $1,109,324.16. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Quantum-Si Price Performance

Shares of Quantum-Si stock traded down $0.05 during trading on Wednesday, hitting $0.83. The stock had a trading volume of 5,042,480 shares, compared to its average volume of 6,078,957. The business has a fifty day moving average of $0.99 and a two-hundred day moving average of $1.04. Quantum-Si Incorporated has a fifty-two week low of $0.69 and a fifty-two week high of $3.10. The firm has a market cap of $180.13 million, a P/E ratio of -1.62 and a beta of 3.18.

Quantum-Si (NASDAQ:QSI) last issued its earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. As a group, research analysts forecast that Quantum-Si Incorporated will post -0.49 earnings per share for the current year.

Institutional Investors Weigh In On Quantum-Si

A number of institutional investors have recently bought and sold shares of QSI. Renaissance Technologies LLC purchased a new position in Quantum-Si during the 1st quarter valued at about $91,000. Hollencrest Capital Management lifted its position in shares of Quantum-Si by 301.1% in the first quarter. Hollencrest Capital Management now owns 40,111 shares of the company’s stock worth $31,000 after purchasing an additional 30,111 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Quantum-Si during the fourth quarter worth approximately $262,000. Invesco Ltd. boosted its holdings in shares of Quantum-Si by 36.2% during the fourth quarter. Invesco Ltd. now owns 402,821 shares of the company’s stock worth $443,000 after purchasing an additional 107,093 shares during the period. Finally, XTX Topco Ltd grew its position in Quantum-Si by 206.9% during the fourth quarter. XTX Topco Ltd now owns 461,982 shares of the company’s stock valued at $508,000 after purchasing an additional 311,450 shares in the last quarter. 39.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on QSI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group cut their target price on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a research note on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $1.00.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.